This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): levetiracetam extended-release
Description: BioMedTracker has separate drug profiles for the IR and XR formulations of Keppra. Please also see Keppra IR.
All historical revenue for Keppra IR and Keppra XR is recorded under Keppra IR.
The precise mechanism(s) by which Keppra exerts its antiepileptic effect is unknown. Keppra binds to the SV2A synaptic vesicle protein. In an animal model, affinity for this protein has been correlated with anti-seizure activity, though its function has not definitively been established.
Keppra XR News
Pink Sheet UCB’s Keppra XR Wins FDA Approval
Additional information available to subscribers only: